ESMO 2014 - Nivolumab: Ph3 Trial Versus Chemo in Previously Treated Advanced Melanoma

Speaker: Michele Maio

M.Maio comments the results of a phase 3 trial using the monoclonal antibody nivolumab in patients whose melanoma has progressed after treatment with ipilimumab. The antibody achieves superior response rates and a longer duration of response than standard #chemotherapy, offering an important new option to #melanoma patients. #ESMO14.http://www.esmo.orgVideo produced by the European Society for Medical Oncology (ESMO)

Discussion Points

  • Rationale for the phase 3 trial of nivolumab
  • Top line results
  • Implications for clinical practice
  • Warrants for further research

Abstract Discussed